<DOC>
	<DOCNO>NCT01976611</DOCNO>
	<brief_summary>This study Post-Marketing Surveillance study Korea evaluate safety efficacy botulinum toxin Type A treat Chronic Migraine clinical practice .</brief_summary>
	<brief_title>Safety Efficacy Botulinum Toxin Type A ( BOTOXÂ® ) Treat Chronic Migraine Korea</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients treat botulinum toxin Type A chronic migraine clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>